Frankfurt
21.02.25
08:05 Uhr
0,144 Euro
-0,001
-0,83 %
-0,83 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | 7 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen | |
| 12.11.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 133 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 17.09.24 | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 337 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen | |
| 21.08.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2024 | 200 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2024 is now available, in Swedish, on the... ► Artikel lesen | |
| 30.07.24 | Isofol Medical AB: Isofol appoints Magdalena Hagman as new Chief Financial Officer | 230 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 30, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive... ► Artikel lesen | |
| 16.07.24 | Isofol Medical AB: Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin | 329 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin.... ► Artikel lesen | |
| 08.05.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-March 2024 | 432 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 8, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-March 2024 is now available, in Swedish, on the... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,644 | +0,44 % | Valneva-Aktie: Wie groß ist ihr Potenzial? | Die Valneva-Aktie schoss Ende Januar/Anfang Februar um +80% in die Höhe, musste aber in den letzten Handelstagen wieder einen Teil ihrer Gewinne abgeben. Heute präsentierte der Impfstoffhersteller seine... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,041 | +6,58 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,645 | +0,04 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,494 | +1,83 % | Where Pacific Biosciences Stands With Analysts | ||
| CARDIOL THERAPEUTICS | 1,168 | +1,39 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for th | Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| CENTOGENE | 0,120 | -36,84 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,865 | -1,74 % | atai Acquires Psilera's DMT Patent Portfolio | ||
| BIOMERIEUX | 112,00 | -0,27 % | bioMérieux S.A. (OTCMKTS:BMXMF) Sees Large Drop in Short Interest | ||
| CYCLACEL | 0,320 | 0,00 % | Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs | BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,177 | +6,63 % | Kia India Begins Production of Syros SUV | Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024New family-focused SUV specifically designed for customers in IndiaGroundbreaking... ► Artikel lesen | |
| GENUS | 20,800 | -1,89 % | Genus Sees H1 Adj. Profit Before Tax Ahead Of Expectations | LONDON (dpa-AFX) - Genus Plc (GNS.L), a biotechnology firm focused on animal genetics, said on Wednesday that it has recorded a strong performance for the first half and expects its earnings... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,390 | +6,11 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 17,300 | -2,81 % | ANAPTYSBIO, INC - 8-K, Current Report | ||
| ABIONYX PHARMA | 1,242 | +5,43 % | ABIONYX Pharma, winner of the France 2030 Plan's "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide | ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant... ► Artikel lesen | |
| MEIRAGTX | 6,800 | -2,16 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,83 % bei einem Aktienkurs von 0,144 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.
